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Introduction: Hereditary lung cancer syndromes are rare, and 
T790M germline mutations of the epidermal growth factor recep-
tor (EGFR) gene predispose to the development of lung cancer. The 
goal of this study was to determine the clinical features and smoking 
status of lung cancer cases and unaffected family members with this 
germline mutation and to estimate its incidence and penetrance.
Methods: We studied a family with germline T790M mutations over 
five generations (14 individuals) and combined our observations with 
data obtained from a literature search (15 individuals).
Results: T790M germline mutations occurred in approximately 1% of 
non–small-cell lung cancer cases and in less than one in 7500  subjects 
without lung cancer. Both sporadic and germline T790M mutations 
were predominantly adenocarcinomas, favored female gender, and 
were occasionally multifocal. Of lung cancer tumors arising in T790M 
germline mutation carriers, 73% contained a second activating EGFR 
gene mutation. Inheritance was dominant. The odds ratio that T790M 
germline carriers who are smokers will develop lung cancer compared 
with never smoker carriers was 0.31 (p = 6.0E-05). There was an over-
representation of never smokers with lung cancer with this mutation 
compared with the general lung cancer population (p = 7.4E-06).
Conclusion: Germline T790M mutations result in a unique hered-
itary lung cancer syndrome that targets never smokers, with a 
preliminary estimate of 31% risk for lung cancer in never smoker 
carriers, and this risk may be lower for heavy smokers. The resultant 
cancers share several features and differences with lung cancers con-
taining sporadic EGFR mutations.
Key Words: EGFR gene, Germline mutation, Hereditary lung cancer 
syndrome, Never smoker status, T790M mutation.
(J Thorac Oncol. 2014;9: 456–463)
Lung carcinomas that initially respond to tyrosine kinase inhibitors (TKIs) often harbor somatic gain-of-function 
mutations in the tyrosine kinase domain of the epidermal growth 
factor receptor (EGFR) gene.1,2 These mutations are more fre-
quently associated with adenocarcinoma histology, female gen-
der, East Asian ethnicity, and low or absent tobacco exposure.3 
Despite initial response to TKI therapy, the tumors usually recur 
or progress by development of acquired resistance.
The major mechanism of acquired resistance is the 
presence of a second EGFR point mutation T790M in exon 
20.4,5 T790M mutations usually occur with a common acti-
vating mutation, and they greatly increase the adenosince 
triphosphate (ATP)-binding affinity of the initial muta-
tion.4,6–9 T790M mutations may occur in treatment naïve 
tumors and cell lines,10,11 and the mutant peaks in sequenc-
ing electropherograms are present in a minority of cells and 
may require sensitive detection methods. By contrast, the 
common activating mutations are often equal to or greater 
than the wild-type peak, a phenomenon we have termed as 
mutant allele-specific imbalance.12 T790M germline muta-
tions are present in 1% of lung cancers undergoing EGFR 
gene sequencing with the mutant allele occurring in about 
equal proportion to the wild-type allele.13
In this report, we describe the development of lung can-
cer in a young woman with a germline T790M mutation, and 
we combined an extensive study of her family pedigree with a 
review of the existing literature.
MATERIALS AND METHODS
Literature Search
We searched the PubMed database using combina-
tions of the terms “Lung Neoplasms,” “Receptor, Epidermal 
Growth Factor,” “Germ-Line,” and “T790M.”
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Investigation of a Family with Germline  
T790M Mutation
Using an institutional review board–approved protocol 
and after informed consent, we were able to track a germline 
T790M mutation in the EGFR gene present in the proband 
and relevant history through five generations of her family. 
The family pedigree was constructed with the assistance of 
the proband and several family members. The smoking his-
tories of deceased individuals were confirmed by at least two 
close relatives. Blood samples were obtained from 17 family 
members representing three generations. Genetic testing of 
the T790M mutation was performed by a Clinical Laboratory 
Improvement Amendments (CLIA)-approved laboratory uti-
lizing EGFR exon 20-specific primers to sequence the region 
containing T790, using a standardized Sanger sequencing 
protocol (BigDye Terminator v3.1 Cycle Sequencing Kit 
Protocol, Applied Biosystems, Foster City, CA).
Detection of EGFR and Germline T790M 
Mutations in Japanese Patients
Paired tumor and nonmalignant lung samples from 
629 Japanese patients with resected lung cancers were 
examined for EGFR mutations using previously published 
methods.14–16 The study received local institutional review 
board permission and all patients gave informed consent for 
mutation testing. Testing was performed for therapy selec-
tion. Two patients were excluded because they had neuro-
endocrine tumors, leaving 627 patients with non–small-cell 
lung cancer (NSCLC).
RESULTS
Literature Search
A search of the PubMed database yielded five refer-
ences for germline T790M mutations.13,17–20
The Proband
The proband was a 29-year-old woman with a total 
tobacco exposure of 0.1 pack-years. She presented with a 
4.4-cm left upper lobe adenocarcinoma and biopsy-proven 
bilateral preneoplastic and preinvasive lesions (Supplemental 
Figure 2, Supplemental Digital Content, http://links.lww.com/
JTO/A545). Analysis of tumor DNA for EGFR exons 18-21 
revealed an L858R mutation in exon 21 (minor peak in com-
parison to the wild-type peak) and a T790M mutation (equiv-
alent in height to the wild-type peak) (Figure 1). Mutation 
analysis of her blood mononuclear cells indicated a T790M 
mutation, with equivalent heights of the mutant and wild-type 
peaks, confirming the presence of a germline T790M mutation. 
No L858R mutation was detected in the mononuclear cells.
History and Mutation Status 
of Proband’s Family
Information about the proband’s family pedigree is pre-
sented in Figure 2 and Supplemental Table 1 (Supplemental 
Digital Content, http://links.lww.com/JTO/A545). Eight of 17 
family members tested were positive for the mutation, includ-
ing the proband’s mother and brother. All family members tested 
received genetic counseling before testing and after the results 
were completed. Two of the family members were tested to estab-
lish lineage (IV:12, III:13) and were subsequently discarded from 
further analysis. Eight of 15 maternally related family members 
tested were mutation positive (53.3%), consistent for Mendelian 
inheritance of an autosomal gene, As documented in Figure 2, 
there are 14 family members who are tested, obligate, or assumed 
carriers of the T790M mutation. Four of these 14 (including the 
proband) developed lung cancer. CT scans, were available on 
five mutation carriers. All scans showed one or multiple small 
pulmonary lesions of uncertain diagnosis (Supplemental data, 
Supplemental Digital Content, http://links.lww.com/JTO/A545).
FIGURE 1.  A cartoon of the location of the 
common mutations in the tyrosine kinase 
domain of the EGFR gene is shown in the 
upper part of the figure (A). Sequencing 
of the EGFR gene in the proband’s adeno-
carcinoma revealed an activating mutation 
(L858R) in the EGFR gene (minor peak) (B) 
and a prominent T790M mutation equal in 
size to the  wild-type peak (B). The T790M 
mutation substitutes methionine for threo-
nine at position 790 (nucleotide c.2369). 
The finding in a lung cancer of a T790M 
mutant band equal in size to the wild-type 
band before tyrosine kinase inhibitor therapy 
suggests a germline mutation. Examination 
of the proband’s blood cells confirmed a 
germline T790M mutation in the patient (C) 
and in her mother (D). 
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Germline T790M Mutations in Lung 
Cancer Cases and Controls
From our proband’s family pedigree and the five reports in 
the literature, there are a total of 29 mutation carriers. Lung can-
cer developed in 19 of these carriers (referred to as lung cancer 
cases (Table 1). The remaining 10 T790M germline cases with-
out lung cancer are referred to as controls. However, the gen-
der and smoking status of some of the cases and controls from 
the literature are lacking or ambiguous. Thus, subgroup analy-
sis contains varying number of cases and controls (Table 2). It 
should be noted that, as with other germline mutation analyses, 
some of the controls may ultimately develop cancer.
Characteristics of Lung Cancers Arising 
in T790M Germline Carriers
As demonstrated in Table 1, there are 19 cancer cases 
known to have arisen in germline carriers including our ped-
igree. All but one of the probands had a family history of 
lung cancer, and the germline mutation status of 11 was con-
firmed by sequencing, one was an obligate carrier, and seven 
family members are assumed to be carriers. In one case 
(case 8), both parents had lung cancer, and the parental inher-
itance could not be determined. Twelve of the 14 patients 
with known ethnicity were Caucasian and two were East 
Indian. Their ages ranged from 29 to 81, and there were 13 
females, five males, and one of unknown gender. The median 
age of the cancer cases was about 63 years, with our proband 
at 29 years being the youngest case identified. Tumor histol-
ogy was available for 14 patients, all of whom had NSCLC, 
and all of whom had one or more adenocarcinomas (case 
9 also had a large cell neuroendocrine carcinoma). Three 
patients had multiple  pathology-documented lung cancers, 
and three had documented invasive cancers and multiple 
bilateral nodules (biopsy proven to be microinvasive cancers 
in one of the cases).21
Of the 22 apparently individual tumors arising in 
11 patients that were tested for EGFR gene mutations and 
FIGURE 2.  Pedigree of family with germline T790M mutation. Age, smoking history, mutation status, and other cancer his-
tory are recorded. *In addition to the three obligate carriers identified in the pedigree, either individual I:1 or I:2 is a obligate 
carrier based on pedigree analysis. Individual III:3 is reported to have died from bladder cancer. She also had lung cancer, but 
it is uncertain if this was a primary cancer or a metastasis. Individual V:1 had a lung carcinoid tumor. These two cases were not 
considered to be lung cancer cases. There are two never smokers who developed lung cancer in the family (II:2 and III:6), given 
the low likelihood that they represent two sporadic cases in this family we have assumed that they are also mutation carriers, 
thus for a total of 14 known, obligate, or assumed mutation carriers.
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16 (73%) had a second activating mutation in addition to the 
T790M germline mutation.
A logistic regression model was used to test the associa-
tion between smoking status and lung cancer among the germ-
line T790M carriers adjusting for sex, as there are more female 
cases whereas more males are represented in the mutation car-
riers that have not developed lung cancer (controls) (Table 2). 
Without adjusting for sex, the odds ratio (OR) for a 2-by-2 
table can be calculated as ad/bc, which is 2 × 4/(5 × 11) = 0.15. 
After taking gender into consideration, it became 0.31 (95% 
confidence interval: [0.04, 2.25]). Although this OR itself was 
not significant (p = 0.34), given the small sample size, it is sig-
nificantly smaller (p = 6.0E-05 by a two-sample mean test) than 
the OR of 40.4 (95% confidence interval: [21.8, 79.6]) esti-
mated from the general U.S. population.22 There was an excess 
of never smokers (NSs) in lung cancer cases arising in germline 
T790M carriers. The proportions of smokers in all lung cancer 
cases were estimated to be 0.91 in males and 0.81 in females.24 
By contrast, only two out of 13 germline T790M derived cases 
(with both sex and smoking status known) were ever smokers 
TABLE 1.  Summary of Literature Regarding Lung Cancer Patients with Germline T790M Mutations and Family Member with 
Lung Cancer (Mutation Status Known and Assumed)
Reference Case Family
Other Family Members 
with Lung Cancer/
Relationship to Proband Ethnicity Age Sex Smoker Tumor
T790M 
Germline 
Mutation
Second EGFR 
Gene Mutation Comment
Bell et al.21 1 1 Proband White 50 M S 5 ADCs Yes 5 tumors L858R in 
2 of 5
Multiple bilateral 
nodules
delL747-T751 in 
1 of 5
Bell et al.21 2 1 Yes, brother White 55 M ? ADC Yes G719A Widespread 
metastases
Bell et al.21 3 1 Yes, mother White 62 F ? ADC Mutation 
assumed
NA
Bell et al.21 4 1 Yes, grandfather White 72 M ? ADC Mutation 
assumed
NA
Girard et al.18 5 2 Proband East Indian 66 F NS ADC Yes L858R Multiple bilateral 
nodules
Girard et al.18 6 2 Yes, father East Indian 41 F NS NA Mutation 
assumed
NA
Girard et al.18 7 3 Proband White 56 M NS ADC Yes L858R Widespread 
metastases
Girard et al.18 8 3 Yes, either father or mother White 72/80 M/F S N/A Mutation 
assumed
NA
Prudkin et al.19 9 4 Proband ? 72 F NS 2 ADCs Yes None in 3 tumors
1 LCNEC
Prudkin et al.19 10 4 Yes, sister ? ? F ? ADC Mutation 
unknown
NA
Oxnard et al.14 11–12 5, 6 One case had a sibling with 
cancer
? 44/73 F/M NS/S ADC Yes Both had exon 19 
deletions
Oxnard et al.14 13 7 No ? 44–73 F NS ADC Yes 6 Nodules—4 had 
L858R, 2 exon 
19 deletions
Tibaldi et al.20 14 8 Proband White 72 F NS ADC Yes Del; E746-A750 
in exon 19
Bilateral 
pulmonary 
lesions
Tibaldi et al.20 15 8 Yes, sister White 74 F NS NSCLC Yes None
UTSW V-3 16 9 Proband White 29 F S ADC Yes L858R
UTSW II-2 17 9 Yes, great-great-aunt of 
proband
White 67 F NS NA Mutation 
assumed
Unknown
UTSW III-6 18 9 Yes, son of case 17 White 56 M NS NA Mutation 
assumed
Unknown
UTSW III-2 19 9 Yes, distant aunt of proband White 81 F NS NA Obligate 
carrier
Unknown
Under “Family history of lung cancer,” the number of family members with lung cancer is indicated in parentheses. The Oxnard reference only provides summary information about 
five germline mutation cases, two of which were previously reported by Girard et al., thus only recorded once. There is both a paternal and a maternal history of lung cancer in case 7 
(Girard et al.) so the lineage is unknown; however, we would assume that one of the parents is a mutation carrier. Please see Supplemental data (Supplemental Digital Content, http://
links.lww.com/JTO/A545) for discussion on potential problems with the report by Tibaldi et al.20
ADC, pulmonary adenocarcinoma; F, female; LCNEC, large cell neuroendocrine carcinoma; M, male; NA, not applicable; NS, never smoker; NSCLC, non–small-cell lung cancer; 
S, smoker; UTSW, University of Texas Southwestern Center.
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(ESs), which was significantly smaller (p = 6.2E-07) than the 
expectation—a conservative estimate 0.81—in the general lung 
cancer cases. The p-value remained significant (p =  7.4E-06) 
even if the two cases of smokers with uncertain gender were 
taken into account, that is, four out of 15 cases were ESs.
Prevalence of T790M Germline 
Mutations in Lung Cancer Patients 
and the General Population
We estimated the overall penetrance of the germline 
mutation and its penetrance in both ESs and NSs without 
regard to age by modeling the conditional probability of fam-
ily phenotypes and genotypes given the proband’s phenotype. 
We estimate the penetrance to be 0.15 and 0.31 in ESs and 
NSs, respectively, and the crude penetrance to be 0.23. We 
examined 627 resected Japanese NSCLC lung cancers for the 
presence of EGFR mutations before the onset of TKI or other 
therapies. Of these cases, 553 were from frozen tissues (552 
tumors, one malignant pleural effusion) and 74 from formalin-
fixed, paraffin-embedded materials of resected tumors. EGFR 
mutations were detected in 209 of 627 samples (33.3%). 
One patient harbored both L858R and an acquired T790M 
mutation. We compared the reported prevalence of germline 
T790M mutations in lung cancer patients in the United States 
(5 of 503)18 with the prevalence in our Japanese cases (0 of 
627) (Fisher’s exact test p-value = 0.017).
As germline T790M mutations predispose to the devel-
opment of lung cancer, the prevalence of germline muta-
tions in lung cancer cases may exceed the prevalence in the 
general population. The T790M mutation was absent in the 
1000 Genomes Project database25 and in the genomes of 6503 
individuals from the NHLBI GO Exome Sequencing Project 
(http://evs.gs.washington.edu/EVS/). Thus, without adjust-
ing for ethnicity, we estimate that the prevalence of germline 
T790M mutations in the general population is less than 1 in 
7500 subjects. Only one T790M germline mutation has been 
identified during non-EGFR gene targeted sequencing—in a 
patient with an unrelated malignancy.26
DISCUSSION
As the rare germline T790M mutations predispose to 
lung cancer, they represent a rare but interesting lung cancer 
familial predisposition gene. Based on the data learned from 
our family, germline T790M is a major cancer predisposi-
tion gene, with an estimated 31% risk for lung cancer in NS 
carriers. We report the investigation of several cases from a 
single family, with the 29-year-old proband inheriting the 
mutation maternally. As we obtained relevant family history 
from several family members for five generations, and tested 
for the germline mutation in members from three generations, 
our family represents the most extensively studied pedigree 
reported. We combined the family data with the scant pub-
lished literature data to summarize our current knowledge of 
this familial form of lung cancer. Our review of the literature 
was complicated by double reporting of some cases,13,17 delib-
erate alteration of some patient data for confidentiality rea-
sons,13 and incorrect or difficult to interpret data from another 
report (Supplemental data, Supplemental Digital Content, 
http://links.lww.com/JTO/A545).20
A comparison of lung cancers arising in patients with 
sporadic activating mutations in the EGFR gene versus can-
cers arising in T790M carriers demonstrates similarities and 
differences (Table 3). Germline T790M mutations are rare, 
and, with the exception of family member testing, are almost 
always detected during analysis of lung cancers for EGFR 
mutations. As germline inheritance predisposes to lung can-
cer, the prevalence in lung cancer cases is likely to be higher 
than in controls without cancer. Vikis et al.9 sequenced the 
probands of 237 families with predisposition to lung cancer, 
but did not identify any germline T790M mutations, confirm-
ing that these mutations are very rare, even in families with 
a genetic predisposition for lung cancer. Although approxi-
mately 1% of NSCLC cases have heterozygous germline 
mutations, an analysis of public databases indicated that the 
prevalence in the general population was probably less than 
one in 7500. Although sporadic EGFR mutations are more 
frequent in lung cancers arising in East Asian ethnicities, our 
data from 627 Japanese cases indicated that the prevalence of 
germline mutations in lung cancer cases in Japan was lower 
than that reported for U.S. cases. To date, not a single case of 
germline T790M mutation has been reported in East Asians.
Almost all of the lung cancers having acquired EGFR 
mutations and those arising in T790M carriers have adeno-
carcinoma histology. While some sporadic adenocarcinomas 
of the lung arise as multiple apparently independent tumors 
and may be associated with multiple preinvasive lesions,25–27 
these findings are characteristic of many inherited cancer syn-
dromes.28–32 We obtained computed tomography (CT) scans of 
six of the germline mutation carriers, including the proband 
and five unaffected carriers. The proband had multiple bilateral 
ground glass and solid nodular lesions, histologically proven 
to represent the entire spectrum of preneoplastic, preinvasive, 
and microinvasive lesions associated with peripheral adeno-
carcinomas.21 One or more subcentimeter solid or ground 
glass nodules of uncertain etiology were identified in all the 
unaffected carriers (Supplemental Table 2, Supplemental 
Digital Content, http://links.lww.com/JTO/A545).
Females were overrepresented in the germline cases. 
Female predominance is present in both lung cancers with 
sporadic EGFR mutations and for germline T790M cases. Of 
TABLE 2.  Distribution of Germline T790M Mutation Carriers 
Stratified by Smoking Status, Gender, and Lung Cancer
Smoking Status Sex Casea,b Controlb
Ever smoker Male 1 5
Female 1 0
Never smoker Male 2 1
Female 9 3
aOut of 19 lung cancer cases, there are two cases with unknown sex and four cases 
with unknown smoking status; overall, there are 13 cases with both sex and smoking 
status known (Table 1). Although there are 10 mutation carriers, we do not know whether 
the proband inherited the mutation from I:1 or I:2 (Figure 2), so we can confirm the 
smoking status and gender in only nine controls.
bCase = Lung cancer arising in germline T790M mutation carrier; control = germline 
mutation carrier that has not developed lung cancer.
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the 22 lung tumors arising in 11 patients whose tumors had 
EGFR gene sequencing, 16 (73%) had a second activating 
mutation. Thus, the important gain-of-function properties of 
these double mutants may explain their frequent presence in 
lung cancers arising in T790M carriers. The median age of 
the cancer cases was about 63 years, with our proband at 29 
years being the youngest case identified. The median age for 
the T790M cases is considerably higher than for breast cancer 
development in BRCA1 carriers (median age, 40 yr), although 
the age ranges are similar.35 Female predominance is present 
in both lung cancers with sporadic EGFR mutations and for 
germline T790M cases.
Perhaps the most interesting and unexpected finding of 
our study was the effect of smoking status on the appearance 
of lung cancer in germline carriers. The distribution between 
smoking status in the germline carriers did not deviate from 
the expected in the U.S. population. However, the distribu-
tion of smoking status among lung cancer cases indicated 
a considerable, highly significant overrepresentation of NSs 
(p = 3.2E-07), based on the expectation that 86% of lung 
cancers in the United States arise in ESs.24 The calculations 
are based on our proband being classified as an ES, even 
though her lifetime tobacco exposure was 0.1 pack-years and 
was highly unlikely to have contributed to the development 
of her lung cancer. We estimated the penetrance to be 0.15 
and 0.31 in ESs and NSs, respectively, and the crude pen-
etrance to be 0.23. However, as we were unable to adjust for 
age and given the small sample size, our estimates must be 
interpreted with caution.
These findings are puzzling, as smoking is univer-
sally accepted as the major risk factor for lung cancer. Our 
hypothetical explanation is illustrated in Figure 3. While the 
T790M mutation is a weak oncogene by itself, when com-
bined with a common activating EGFR mutation such as 
L858R, the oncogenic potential of both mutations is greatly 
enhanced, and 73% of lung cancers arising in germline carri-
ers contained a second activating mutation. Multiple studies 
have demonstrated that sporadic activating EGFR mutations 
favor never smoking status and female gender.3 KRAS muta-
tions, a major driver mutation in adenocarcinomas arising in 
ESs, are mutually exclusive with EGFR mutations.3,33 Because 
somatic mutations of EGFR and KRAS are mutually exclu-
sive, germline T790M mutations and KRAS mutations in ES 
carriers may also be mutually exclusive. Thus, second acti-
vating EGFR mutations in germline carriers may arise more 
frequently in NSs and women and predispose to cancer devel-
opment. Of interest, both lung cancers with sporadic EGFR 
mutations and the germline T790M cases favor female gen-
der, adenocarcinoma histology, and never smoking status. 
However, one notable difference is the absence of reported 
T790M germline mutations in those of East Asian ethnicity.
The management and prevention of lung cancers in 
germline carriers present unusual and possibly controversial 
options. The presence of the T790M mutation with or with-
out being accompanied by a more typical activating muta-
tion at presentation predicts for resistance to the standard 
TKIs. The only germline cases reported to have received 
TKI therapy were the two sisters reported by Tibaldi et al.,20 
FIGURE 3.  Hypothetical  mutation-driven pathways to NSCLC development in patients with and without germline T790M 
mutations. In subjects without the germline mutation, the major pathways are via EGFR mutations (in NS) or via KRAS mutations 
(in ES), although other driver mutations may occur in either group. Subjects with germline T790M mutations, a weak driver 
mutation, usually require one or more other driver mutations for NSCLC development. In NS, the second mutation is usually 
another EGFR mutation although other pathways may occasionally be activated. In ES, the presence of the germline EGFR gene 
mutation and the smoking status decrease or preclude the possibility of developing a KRAS mutation, although alternative driver 
mutations may occasionally occur. ES, ever smoker; NS, never smoker; NSCLC, non–small-cell lung cancer.
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who had partial responses. Thus, in the absence of another 
known or suspected molecular target, conventional chemo-
therapy seems to be the preferred first-line therapy option. 
Several newer third- and even fourth-generation TKIs have 
entered clinical trial, and some were designed to overcome 
T790M-mediated resistance34,35 and offer the possibility of 
effective targeted therapy in the future. Regular CT scans are 
one method for the early detection of lung cancers develop-
ing in carriers, and the carriers in the family of our proband 
are being offered this option. Clearly, optimal management 
and prevention strategies will require more information 
obtained from observation, prevention, and therapy of many 
more carriers and cases. For these reasons, The Dana-Farber 
Cancer Institute has initiated the “INHERIT EGFR study: 
Investigating the hereditary risk from T790M” (http://clini-
caltrials.gov/ct2/show/NCT01754025).
CONCLUSIONS
Germline T790M mutations result in a very rare and 
unique lung cancer hereditary syndrome that targets female 
NSs. The risk of lung cancer development in never smoking 
carriers is greater than the risk of heavy smokers with or with-
out the mutation. Unaffected carriers with this mutation are 
at increased risk for developing lung cancer irrespective of 
their smoking status and should be followed by increased sur-
veillance including low-dose CT scans. The resultant cancers 
share several features with lung cancers containing sporadic 
EGFR mutations and known or suspected differences.
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